Randox Provides Improved Stroke and Heart Attack Patient Profiling

Randox now offers Metabolic Syndrome Arrays for the simultaneous determination of analytes associated with Metabolic Syndrome and related disorders for improved patient profiling. Individuals with Metabolic Syndrome are more likely to have a stroke, heart attack or develop type 2 diabetes.

Metabolic Syndrome is a clustering of cardiovascular risk factors with approximately 20-25% of adults affected. Individuals with Metabolic Syndrome are three times more likely to have a stroke or heart attack and five times more likely to develop type 2 diabetes, highlighting the seriousness of the syndrome. The pathophysiological pathways which lead to this condition however, remain unclear. The IDF Metabolic Syndrome worldwide definition states that an individual must have central obesity plus at least two of the following four factors; raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting plasma glucose.

Metabolic Syndrome Array I includes these analytes; C-peptide, Ferritin, IL-1α, IL-6, Insulin, Leptin, Plasminogen Activator Inhibitor-I, Resistin and Tumour Necrosis Factor α. Metabolic Syndrome Array II includes; Adiponectin, CRP and Cystatin C. Utilising proven multiplexing Biochip technology, these arrays provide cost and time savings as multiple assays can be run on one sample. The Metabolic Syndrome Arrays are suitable for use on plasma and serum, using only 100 µl of sample to measure all analytes on each array. Randox also offer a complete range of multi-analyte controls and calibrators to ensure reliable results.